Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM).
With Startup, Researchers Plan To Help Growers Feed More People, Preserve Environment (UF News)
UF startup EZ Ag Innovations, founded by UF researchers Nathan Boyd and Arnold Schumann, is using AI-powered precision-spraying technology to help farmers reduce chemical use, lower costs, and improve sustainability in agriculture.
LightPath Technologies Receives $4.8 Million Purchase Order for Advanced Infrared Camera Systems (PR Newswire)
UF startup LightPath Technologies announced it has received a $4.8 million purchase order with an existing customer related to the supply of advanced infrared camera systems for public safety applications.
iOncologi Secures Foundational U.S. Patent As Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival With Cancer Immunotherapy (Bio Space))
UF startup iOncologi, Inc. announced that USPTO has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Rise Therapeutics Secures New Funding To Advance First-in-Class R-2487 Oral Immune Biomodulator Into Sjogren’s Disease Clinical Testing (Bio Space)
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, announced it will be initiating clinical evaluation of R-2487 in SjD.
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Optym Launches LoadAi, Bringing Real-Time Decision Intelligence to Truckload Dispatching (Cision PR Web)
UF startup Optym announced the launch of LoadAi, an AI-powered operations platform built to help truckload carriers reduce empty miles, optimize dispatch decisions, and scale planner productivity across their networks.
LightPath Technologies Awarded $22.1 Million Follow-On Purchase Order To Supply Advanced Infrared Camera Systems (PR Newswire)
UF startup LightPath Technologies, Inc., announced it has secured $22.1 million in follow-on purchase orders with a leading global technology customer related to the supply of advanced infrared camera systems in CY 2027.
Nasser Nassiri Koopaei Is on a Mission to Address Unmet Medical Needs With His Biotechnology Startup (UF Pharmacy)
UF researcher Nasser Nassiri Koopaei has been working to transform his research on stem cell-derived extracellular vesicles for targeted drug delivery through his biotechnology startup, EriVan Bio, a UF startup.